Skip to main content

Advertisement

Table 1 Demographic characteristics of the included studies

From: Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials

Author Study design Target Population Treatment duration n Study groups Age, years Female, n (%) BMI, kg/m2 Total cholesterol, mg/dL LDL-C, mg/dL HDL-C, mg/dL Triglycerides, mg/dL Lp(a), mg/dL Lp(a) change, mg/dL
Athyros et al. (2002) [52] Randomized, open-label trial Type 2 diabetes and combined hyperlipidemia 24 weeks 40 40 40 Atorvastatin 20 mg/day Fenofibrate 200 mg/day Atorvastatin 20 mg/day + fenofibrate 200 mg/day 57 (44–67)a 58 (48–69)a 58 (50–68)a 17 (42.5) 18 (45.0) 17 (42.5) ND ND ND 252 ± 17 253 ± 17 255 ± 19 161 ± 15 163 ± 15 163 ± 16 34.6 ± 3.2 34.8 ± 3.4 35.1 ± 3.5 278 ± 24 281 ± 24 278 ± 23 18.4 ± 3.7 20.1 ± 5.2 19.2 ± 4.1 2.0 –4.0 1.0
Bredie et al. (1996) [55] Randomized, double-blind, placebo-controlled trial Familial combined hyperlipidemia 12 weeks 41 40 Simvastatin 20 mg/day Gemfibrozil 1200 mg/day 50.4 ± 10.8 53.4 ± 9.4 9 (21.9) 14 (35.0) 26.6 ± 2.7 27.2 ± 3.0 282.2 ± 37.1 290.0 ± 37.8 149.6 ± 37.8 157.7 ± 38.2 32.4 ± 7.3 35.1 ± 7.7 283.4 ± 106.2 285.2 ± 108.0 19.6b 18.0b 6.5 2.7
Hansen et al. (1994) [60] Randomized, cross-over trial Familial defective apolipoprotein B-100 8 weeks 17 13 Pravastatin 40 mg/day Gemfibrozil 1200 mg/day 45.8 ± 17.1 40.8 ± 12.3 12 (70.5) 7 (53.8) ND ND 320.9 ± 58.0 320.9 ± 46.4 247.4 ± 54.1 235.8 ± 42.5 46.4 ± 7.7 50.2 ± 19.3 115.1 (79.7–168.2)a 141.7 (106.2–230.2)a 10.5 (3.5–16.7)a 8.3 (3.4–12.9)a 0.9 1.1
Perez-Jimenez et al. (1995) [61] Randomized, cross-over trial Patients with heart transplant 8 weeks 18 18 Lovastatin 10 mg/day Bezafibrate 400 mg/day 54 ± 2 2 (11.1) ND 302 ± 7 307 ± 5 213 ± 5 212 ± 5 54 ± 3 51 ± 4 170 ± 15 201 ± 17 34 ± 9 37 ± 9 5.0 –13.0
Melenovsky et al. (2002) [51] Randomized, open-label, cross-over trial Combined hyperlipidemia 10 weeks 15 14 Fenofibrate 200 mg/day Atorvastatin 10 mg/day 48.0 ± 6.9 46.4 ± 8.9 ND ND 27.7 ± 2.3 27.9 ± 3.2 300.0 ± 56.4 283.0 ± 35.9 174.7 ± 46.4 165.8 ± 23.2 49.4 ± 8.8 47.9 ± 15.8 492.4 ± 440.2 465.0 ± 372.8 24 ± 29 17 ± 23 2.8 1.8
Ohrvall et al. (1995) [54] Randomized, double-blind, cross-over trial Diabetes and hyperlipo-proteinemia 4 months 25 24 Gemfibrozil 1200 mg/day Simvastatin 10 mg/day 63.7 (48–78)a 9 (31.0) ND 232.0 ± 40.2 152.7 ± 43.3 36.7 ± 6.9 116.0 ± 52.5 37.77 ± 54.75 –7.0 –2.4
Ramires et al. (1995) [62] Randomized clinical trial Hyperlipidemia and hyperlipo-proteinemia 12 weeks 14 13 Gemfibrozil 1200 mg/day Lovastatin 40-80 mg/day 54 ± 7 55 ± 9 5 (55.5) 3 (30.0) ND ND 298.9 ± 12.3 299.3 ± 11.2 209.9 ± 20.8 208.0 ± 11.9 31.7 ± 7.3 34.4 ± 6.1 295.8 ± 23.0 281.6 ± 20.3 29.8 ± 5.7 27.8 ± 4.1 –7.5 1.4
Bairaktari et al. (1999) [50] Open-label trial Mixed hyperlipidemia 16 weeks 45 46 Atorvastatin 10 mg/day Fenofibrate 200 mg/day 49 ± 8 46 ± 10 16 (35.5) 15 (32.6) 26.8 ± 4 27.4 ± 3 278 ± 34 282 ± 37 198 ± 29 199 ± 36 40 ± 11 36 ± 16 271 ± 59 269 ± 60 14 ± 12 11.8 ± 10.5 1.2 –1.8
Davidson et al. (2009) [53] Randomized, double-blind trial Dyslipidemia 12 weeks 74 73 73 Atorvastatin 40 mg/day Fenofibrate 145 mg/day Atorvastatin 40 mg/day + fenofibrate 100 mg/day 56.3 ± 9.8 56.4 ± 10.5 54.9 ± 10.7 39 (52.7) 33 (45.2) 33 (45.2) ND ND ND 254.4 ± 44.2 251.9 ± 47.5 252.0 ± 40.1 165.0 ± 37.7 166.6 ± 46.7 156.2 ± 33.6 42.7b 41.2b 43.3b 265.1b 227.3b 270.2b 69.0 ± 67.5 66.0 ± 65.3 76.8 ± 74.5 9.3 5.1 6.9
Greten et al. (1994) [64] Randomized, double-blind trial Primary hypercholesterolemia 12 weeks 64 67 Fluvastatin 40 mg/day Bezafibrate 400 mg/day 53.0 (18–75)a 51.8 (22–70)a 37 (57.8) 37 (55.2) 24.6 (18.6–31.2)a 24.7 (16.9–31.6)a 352.7 ± 89.4 340.3 ± 76.7 268.9 ± 88.5 257.4 ± 75.6 55.2 ± 12.2 55.2 ± 12.6 143.2 ± 48.0 138.0 ± 59.4 12.0 ± 16.5 14.0 ± 30.0 1.0 0.4
Kehely et al. (1995) [56] Randomized, double-blind trial Mixed hyperlipidemia 3 months 53 27 26 Placebo Simvastatin 20 mg/day Bezafibrate 400 mg/day ND 52 ± 9 49 ± 10 ND 11 (40.7) 4 (15.3) ND ND ND 298.5 ± 51.8 189.0 ± 54.9 42.5 ± 8.1 286.9 ± 122.2 19.8 ± 2.8 5.7 –2.5
May et al. (2008) [57] Randomized, double-blind, placebo-controlled trial Diabetes and mixed dyslipidemia 12 weeks 100 100 100 Fenofibrate 160 mg/day Simvastatin 20 mg/day Fenofibrate 160 mg/day + Simvastatin 20 mg/day 61.6 ± 11.5 135 (45.0) ND ND ND ND ND ND ND ND ND ND ND ND ND 4.0 (2.0–6.0)a 4.0 (2.0–6.0)a 5.0 (3.0–9.0)a 1.0 1.0 0.0
Ramires et al. (1997) [63] Randomized clinical trial Hypercholesterolemia and hyperlipoproteinemia 12 weeks 14 13 Gemfibrozil 1200 mg/day Lovastatin 40-80 mg/day 54 ± 7 55 ± 9 5 (36.0) 6 (59.0) ND ND 306 ± 13 307 ± 11 215 ± 21 213 ± 12 33 ± 7 35 ± 6 294 ± 23 280 ± 20 51 ± 10 48 ± 7 –13.0 –2.0
Saougos et al. (2007) [65] Clinical trial Hyperlipidemia 2 months 50 50 Rosuvastatin 10 mg/day Fenofibrate 200 mg/day 54.6 ± 14.6 55.9 ± 11 31 (62.0) 30 (60.0) 25.8 ± 4.2 34.3 ± 7 297.7 ± 50.2 235.8 ± 34.8 208.8 ± 42.5 146.9 ± 34.8 58.0 ± 11.6 50.2 ± 11.6 141.7 ± 53.1 239.1 ± 53.1 4.0 (2.0–7.4)a 3.8 (2.0–7.9)a 0.0 0.1
Vigna et al. (1999) [58] Randomized, double-blind trial Men with mixed hyperlipidemia 2 months 15 15 Gemfibrozil 1200 mg/day Simvastatin 20 mg/day 53.6 ± 11.7 50.9 ± 9.9 0 (0.0) 0 (0.0) 26.7 ± 1.9 25.0 ± 2.5 280.2 ± 30.1 281.2 ± 38.8 208.5 ± 30.1 206.7 ± 37.8 46.1 ± 9.9 44.4 ± 8.2 46.1 ± 9.9 44.4 ± 8.2 25.7 ± 22.6 9.2 ± 11.8 –4.3 2.1
de Lorgeril et al. (1999) [59] Randomized, double-blind trial Dyslipidemic coronary patients 12 weeks 32 32 Fenofibrate 200 mg/day Simvastatin 20 mg/day ND ND ND 278.4 ± 27.0 278.4 ± 27.0 193.3 ± 27.0 197.2 ± 23.2 46.4 ± 11.6 46.4 ± 7.7 186.0 ± 79.7 168.2 ± 88.5 34 ± 62 32 ± 39 –6.0 –2.0
  1. Values are expressed as mean ± SD
  2. aMedian (interquartile range)
  3. bMean only
  4. BMI body mass index, ND no data